Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2024-02-14 | CITADEL ADVISORS LLC | VYNE Therapeutics Inc. | - | 8.5% | EDGAR |
SC 13G/A | 2024-02-02 | Soleus Capital Master Fund, L.P. | VYNE Therapeutics Inc. | 703,868 | 5.0% | EDGAR |
SC 13D | 2023-11-13 | AI Biotechnology LLC | VYNE Therapeutics Inc. | 3,201,980 | - | EDGAR |
SC 13G | 2023-11-13 | Cormorant Asset Management, LP | VYNE Therapeutics Inc. | 1,394,336 | - | EDGAR |
SC 13G | 2023-11-13 | CITADEL ADVISORS LLC | VYNE Therapeutics Inc. | - | 8.5% | EDGAR |
SC 13G | 2023-11-13 | EVENTIDE ASSET MANAGEMENT, LLC | VYNE Therapeutics Inc. | 1,394,336 | 10.0% | EDGAR |
SC 13G | 2023-11-02 | Soleus Capital Master Fund, L.P. | VYNE Therapeutics Inc. | 890,868 | 6.4% | EDGAR |
SC 13G/A | 2022-02-15 | PERCEPTIVE ADVISORS LLC | VYNE Therapeutics Inc. | 2,425,604 | 4.5% | EDGAR |
SC 13G/A | 2021-08-25 | PERCEPTIVE ADVISORS LLC | VYNE Therapeutics Inc. | 4,987,887 | 9.6% | EDGAR |
SC 13G/A | 2021-07-12 | BlackRock Inc. | VYNE Therapeutics Inc. | 1,037,677 | 2.0% | EDGAR |
SC 13G/A | 2021-02-16 | Point72 Asset Management, L.P. | VYNE Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2021-02-16 | FIRST MANHATTAN CO | VYNE Therapeutics Inc. | 21,319 | 0.0% | EDGAR |
SC 13G/A | 2021-02-16 | GREAT POINT PARTNERS LLC | VYNE Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2021-02-16 | PERCEPTIVE ADVISORS LLC | VYNE Therapeutics Inc. | 27,095,819 | 14.3% | EDGAR |
SC 13G/A | 2021-02-11 | JANUS HENDERSON GROUP PLC | VYNE Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2021-02-02 | BlackRock Inc. | VYNE Therapeutics Inc. | 11,988,767 | 7.1% | EDGAR |
SC 13G/A | 2020-06-11 | Vivo Capital VIII, LLC | Menlo Therapeutics Inc. | 3,643,824 | 2.2% | EDGAR |
SC 13G | 2020-06-11 | PERCEPTIVE ADVISORS LLC | Menlo Therapeutics Inc. | 22,876,410 | 14.0% | EDGAR |
SC 13D/A | 2020-04-16 | venBio Global Strategic Fund II L.P. | Menlo Therapeutics Inc. | 0 | 0.0% | EDGAR |
SC 13G/A | 2020-02-14 | GREAT POINT PARTNERS LLC | Menlo Therapeutics Inc. | 1,652,013 | 6.8% | EDGAR |